# Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05366868` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05366868](<https://clinicaltrials.gov/study/NCT05366868>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05366868

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 567 participants.

## Technical summary

Registry record NCT05366868. Randomized; no masking; primary purpose treatment. Start 2022-05-26 (actual); primary completion 2026-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 567 participants (planned count; ClinicalTrials.gov record NCT05366868, source copy `cardio:ctgov-nct05366868-2026-04-09`, retrieved 2026-10-26)
- Started: 2022-05-26 (actual) (ClinicalTrials.gov record NCT05366868, source copy `cardio:ctgov-nct05366868-2026-04-09`, retrieved 2026-10-26)
- Primary completion: 2026-08-31 (anticipated) (ClinicalTrials.gov record NCT05366868, source copy `cardio:ctgov-nct05366868-2026-04-09`, retrieved 2026-10-26)
- Completion: 2027-03-31 (anticipated) (ClinicalTrials.gov record NCT05366868, source copy `cardio:ctgov-nct05366868-2026-04-09`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT05366868, source copy `cardio:ctgov-nct05366868-2026-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05366868-2026-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Imeglimin
- Intervention (Drug): Metformin
- Intervention (Drug): Vildagliptin
- Lead sponsor: National Center for Global Health and Medicine, Japan
- Lead sponsor class: OTHER\_GOV
- Collaborator: Sumitomo Pharma Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 13be24372283d446ba8b0a2d6633bbc7ad02a75846e79259c0d05bba2acb56b6
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
